EP Patent

EP2153830A1 — Use of dronedarone for the preparation of a medicament intended for the prevention of stroke or transient ischemic attack

Assigned to Sanofi Aventis France · Expires 2010-02-17 · 16y expired

What this patent protects

Use of dronedarone for the preparation of a medicament intended for the prevention of stroke or transient ischemic attack.

USPTO Abstract

Use of dronedarone for the preparation of a medicament intended for the prevention of stroke or transient ischemic attack.

Drugs covered by this patent

dronedarone-hydrochloride (DRONEDARONE HYDROCHLORIDE)

Patent Metadata

Patent number: EP2153830A1
Jurisdiction: EP
Classification: —
Expires: 2010-02-17
Drug substance claim: No
Drug product claim: No
Assignee: Sanofi Aventis France
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.